Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Neuropathies and almitrine. 14 cases].

H Petit1, D Leys, J F Hurtevent

  • 1Service de Neurologie, Centre Hospitalier Régional et Universitaire de Lille.

Revue Neurologique
|January 1, 1987
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Acute stroke care in France: Survey in the 138 stroke units.

Revue neurologique·2022
Same author

Spinal infarcts.

Revue neurologique·2021
Same author

The first case of traumatic internal carotid arterial dissection? Verneuil's case report from 1872.

Revue neurologique·2020
Same author

EAN/ERS/ESO/ESRS statement on the impact of sleep disorders on risk and outcome of stroke.

European journal of neurology·2020
Same author

How can neurology be affected by the '100 Radical Innovation Breakthroughs for the Future' report of the European Commission?

European journal of neurology·2020
Same author

Cerebral ischaemia with unknown onset: Outcome after recanalization procedure.

Revue neurologique·2019

Almitrine therapy can cause peripheral neuropathies, even in patients without respiratory issues. Long-term follow-up shows slow recovery, with persistent sensory loss and improved nerve conduction velocities.

Area of Science:

  • Neurology
  • Clinical Pharmacology

Context:

  • Peripheral neuropathies are a known adverse effect of almitrine therapy.
  • Previous studies had limited follow-up periods after drug discontinuation.

Purpose:

  • To evaluate clinical and electrophysiological outcomes 6-12 months after discontinuing almitrine therapy.
  • To assess the long-term impact of almitrine on peripheral nerves.

Summary:

  • Nine patients receiving almitrine (alone or with raubasine) were studied 6-12 months post-therapy.
  • Findings revealed sensory peripheral neuropathies, distal axonopathy, and slow but ongoing improvement in nerve function.
  • Almitrine-induced neuropathy can occur without chronic respiratory insufficiency and may be dose-dependent in predisposed individuals.

Related Experiment Videos

Impact:

  • This study highlights the potential for persistent peripheral nerve damage from almitrine.
  • It suggests cautious prescription of almitrine, especially in patients with pre-existing neuropathy risk factors.
  • Regular interruption of almitrine treatment is recommended.